Is Descovy approved for HIV PrEP?
Yes. Descovy (emtricitabine/tenofovir alafenamide, or FTC/TAF) is approved as HIV pre-exposure prophylaxis (PrEP) to reduce the risk of getting HIV from sex in certain adults who are at risk. [1]
Who can use Descovy for PrEP?
The approval is for adults and adolescents weighing at least 35 kg. It is used for people at risk from receptive anal sex? The key limitation is that Descovy for PrEP is not approved for people at risk from receptive vaginal sex, because clinical data were not established for that use. [1]
How is Descovy different from Truvada for PrEP?
Both Descovy and Truvada are combination medicines used as PrEP, but they are not identical in approvals. Descovy is not indicated for receptive vaginal sex, while Truvada has broader PrEP indications for sexual and injection-related risk. [1]
What dosing and follow-up usually apply to PrEP?
As with other PrEP products, clinicians typically require recent HIV testing before starting and ongoing HIV testing while on treatment to confirm the person stays HIV-negative and to reduce resistance risk if someone becomes infected. (Your prescriber will set the schedule.) [1]
What should people ask their clinician before starting Descovy for PrEP?
Patients commonly ask about:
- Whether their specific exposure risk matches Descovy’s approved indications (especially receptive vaginal sex). [1]
- Baseline kidney function and ongoing monitoring, since tenofovir-based PrEP products can affect kidney health.
- Whether there are drug interactions or other conditions that could change suitability.
Sources
[1] DrugPatentWatch.com – Descovy (emtricitabine/tenofovir alafenamide) information and related regulatory/patent context: https://www.drugpatentwatch.com/patent/descovy